Peregrine Pharmaceuticals Inc.(PPHM)- NASDAQ
  • Fri, Sep. 9, 7:30 AM
    • Peregrine Pharmaceuticals (PPHM) FQ1 results: Revenues: $5.6M (-42.3%); Operating Loss: ($11.1M) (+19.0%); Net Loss: ($12.4M) (+17.9%); Loss Per Share: ($0.05) (+37.5%); Quick Assets: $44.2M (-28.0%).
    • FY2017 Guidance: Revenues: $50M - 55M.
    | Fri, Sep. 9, 7:30 AM
  • Thu, Sep. 8, 4:08 PM
    • Peregrine Pharmaceuticals (NASDAQ:PPHM): FQ1 EPS of -$0.05 misses by $0.01.
    • Revenue of $5.6M (-42.1% Y/Y) misses by $7.49M.
    • Press Release
    | Thu, Sep. 8, 4:08 PM | 3 Comments
  • Wed, Sep. 7, 5:35 PM
    | Wed, Sep. 7, 5:35 PM | 4 Comments
  • Fri, Jul. 15, 7:18 AM
    • Peregrine Pharmaceuticals (PPHM) FQ4 results: Revenues: $18.8M (+102.2%); Total Costs & Expenses: $30.7M (+42.8%); Net Loss: ($13.3M) (+1.5%); Loss Per Share: ($0.05) (+28.6%).
    • FY2016 results: Revenues: $44.7M (+66.8%); Total Costs & Expenses: $101M (+30.7%); Net Loss: ($60.1M) (-11.1%); Loss Per Share: ($0.28) (+6.7%); Quick Assets: $61.4M (-9.7%).
    • FY2017 Guidance: Contract Manufacturing Revenue: $50M - 55M.
    | Fri, Jul. 15, 7:18 AM
  • Thu, Jul. 14, 6:30 PM
    • Micro-cap Peregrine Pharmaceuticals (NASDAQ:PPHM), up 11.6% today, has dipped 2.1% after hours following a miss on its Q2 profits.
    • Revenues more than doubled and beat expectations. Current contract manufacturing commitments from Avid third-party customers are about $68M; based on that backlog, Peregrine sees fiscal 2017 contract manufacturing revenues of $50M-$55M.
    • Net loss narrowed overall, to $13.3M ($0.05/share) from a previous $13.51M ($0.07/share).
    • The company had cash and equivalents of $61.4M as of April 30, vs. a year-ago $68M.
    • Press Release
    | Thu, Jul. 14, 6:30 PM | 5 Comments
  • Thu, Jul. 14, 4:08 PM
    • Peregrine Pharmaceuticals (NASDAQ:PPHM): FQ4 EPS of -$0.05 misses by $0.02.
    • Revenue of $18.78M (+101.7% Y/Y) beats by $2.98M.
    • Shares +5%.
    • Press Release
    | Thu, Jul. 14, 4:08 PM | 1 Comment
  • Wed, Jul. 13, 5:35 PM
  • Wed, Mar. 9, 9:14 AM
    • Peregrine Pharmaceuticals (PPHM) FQ3 results: Revenues: $6.7M (+17.5%); R&D Expense: $15.2M (+34.5%); SG&A: $4.5M (+4.7%); Operating Loss: ($16.9M) (-30.0%); Net Loss: ($18.2M) (-30.0%); Loss Per Share: ($0.08) (unch); Quick Assets: $67.5M (-0.7%).
    • No guidance given.
    | Wed, Mar. 9, 9:14 AM
  • Wed, Mar. 9, 8:03 AM
    • Peregrine Pharmaceuticals (NASDAQ:PPHM): FQ3 EPS of -$0.08 misses by $0.01.
    • Revenue of $6.71M (+18.1% Y/Y) misses by $1.25M.
    | Wed, Mar. 9, 8:03 AM
  • Tue, Mar. 8, 5:30 PM
    | Tue, Mar. 8, 5:30 PM | 1 Comment
  • Fri, Feb. 26, 3:58 PM
    • Achillion Pharmaceuticals (ACHN +7.4%) upgraded to Outperform from Neutral with a $10 (36% upside) price target by Baird
    • Insulet (PODD +8.5%) upgraded to Buy from Hold with a $40 (25% upside) price target by Benchmark.
    • DENTSPLY (XRAY -0.1%) upgraded to Neutral from Sell by UBS. Price target raised to $60 (1% downside risk) from $50.
    • PTC Therapeutics (PTCT -29.4%) upgraded Hold from Underperform by Jefferies. Price target lowered to $12 (22% upside) from $18.
    • AbbVie (ABBV -0.3%) upgraded to Buy from Neutral by Citigroup. Price target raised to $65 (16% upside) from $56.
    • Wellcare Health Plans (WCG +0.7%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $114 (24% upside) from $80.
    • Keryx Biopharmaceuticals (KERX +8.7%) downgraded to Neutral from Overweight by JP Morgan.
    • Peregrine Pharmaceuticals (PPHM -62.1%) downgraded to Neutral from Buy with a $0.50 (25% upside) price target by Roth Capital.
    • EXACT Sciences (EXAS -1.8%) downgraded to Neutral from Buy by Roth Capital and Equal Weight from Overweight by Stephens & Co.
    • Radius Health (RDUS -2.8%) downgraded to Hold from Buy with a $37 (23% upside) price target by Jefferies.
    • PTC Therapeutics (PTCT -29.4%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $13 (56% upside) from $90.
    • Orexigen (OREX -31.9%) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $2 (104% upside) from $4.50.
    • Express Scripts (ESRX +2.4%) downgraded to Sell from Hold by Deutsche Bank. Price target lowered to $61(15% downside risk) from $93.
    • Perrigo (PRGO) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $124 (4% downside risk) from $160.
    • Chimerix (CMRX -6.6%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $9 (91% upside) from $13.
    | Fri, Feb. 26, 3:58 PM | 8 Comments
  • Fri, Feb. 26, 12:45 PM
    | Fri, Feb. 26, 12:45 PM | 4 Comments
  • Fri, Feb. 26, 11:52 AM
    • Nano cap Peregrine Pharmaceuticals (PPHM -62.6%) craters on more than 10x normal volume in response to its announcement that lead product candidate, Fast Track-tagged bavituximab, failed a Phase 3 clinical trial, SUNRISE, in patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
    • The company terminated the trial based on the recommendation of the Independent Data Monitoring Committee following a pre-planned interim analysis after 33% of the targeted events (patient deaths) occurred. The results did not show a sufficient improvement in overall survival (OS) in the bavituximab plus docetaxel cohort compared to the docetaxel-only group. The problem was not bavituximab, which performed as expected, but docetaxel, which significantly outperformed expectations as measured by OS.
    • Despite the setback, the company remains committed to advancing bavituximab combination studies such as the one with AstraZeneca's(AZN -0.9%) durvalumab.
    • Bavituximab is a monoclonal antibody that binds to a cell membrane component called phosphatidylserine, a highly immunosuppressive molecule that is usually resides inside the membrane of healthy cells. In tumor blood vessels, however, it becomes exposed on the outside of cells, thereby creating a target for anticancer therapies.
    • Previously: Peregrine Pharma, AstraZeneca to collaborate on immuno-oncology trial (Aug. 24, 2015)
    | Fri, Feb. 26, 11:52 AM | 8 Comments
  • Fri, Feb. 26, 9:17 AM
    | Fri, Feb. 26, 9:17 AM | 7 Comments
  • Dec. 11, 2015, 6:25 AM
    • Peregrine Pharmaceuticals (PPHM +1.7%) FQ2 results: Revenues: $9.5M (+50.8%); R&D Expense: $14.2M (+42.0%); SG&A: $4.4M (+2.3%); Operating Loss: ($13.8M) (-14.0%); Net Loss: ($13.2M) (-9.1%); Loss Per Share: ($0.07) (unch); Quick Assets: $72M (+5.9%).
    • FY2016 Guidance: Third-party contract manufacturing revenue: $35M - 40M from $30M - $35M.
    | Dec. 11, 2015, 6:25 AM | 1 Comment
  • Dec. 10, 2015, 4:08 PM
    • Peregrine Pharmaceuticals (NASDAQ:PPHM): FQ2 EPS of -$0.07 beats by $0.02.
    • Revenue of $9.52M (+51.1% Y/Y) beats by $2.02M.
    | Dec. 10, 2015, 4:08 PM | 2 Comments